Vyvanse® (lisdexamfetamine dimesylate) – New formulation approval
January 28, 2017 – The FDA approved Shire’s Vyvanse (lisdexamfetamine dimesylate) chewable tablets, for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6 years and older and moderate to severe binge eating disorder (BED) in adults.
Top